IDH1 and endometrial cancer: Notably, wild‐type IDH1 is enriched in endometrial cancer, whereas IDH1 mutations are rare.[23] Our previous work reported that the aberrant expression of IDH1 lowers the therapeutic response to chemotherapy in endometrial cancer[23]; however, the functional consequences of IDH1 activity in endometrial cancer and its effect on the therapeutic response to progestin therapy are yet to be explored.